Literature DB >> 15350014

Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria.

Matteo Ravaioli1, Giorgio Ercolani, Matteo Cescon, Gaetano Vetrone, Claudio Voci, Walter Franco Grigioni, Antonia D'Errico, Giorgio Ballardini, Antonino Cavallari, Gian Luca Grazi.   

Abstract

The selection criteria in liver transplantation for HCC are a matter of debate. We reviewed our series, comparing two periods: before and after 1996, when we started to apply the Milan criteria. The study population was composed of patients with a preoperative diagnosis of HCC, confirmed by the pathological report and with a survival of >1 year. Preoperative staging as revealed by radiological imagining was distinguished from postoperative data, including the variable of tumor volume. After 1996 tumor recurrences significantly decreased (6 out of 15 cases, 40% vs. 3 out of 48, 6.3%, P < .005) and 5-year patient survival improved (42% vs. 83%, P < .005). Not meeting the Milan criteria was significantly related to higher recurrence rate (37.5% vs. 12.7%, P < .05) and to lower 5-year patient survival (38% vs. 78%, P < .005%) in the preoperative analysis, but not in the postoperative one. The alfa-fetoprotein level of more than 30 ng/dL and the preoperative tumor volume of more than 28 cm3 predicted HCC recurrences in the univariate and mutivariate analysis (P < .005 and P < .05, respectively). The ROC curve showed a linear correlation between preoperative tumor volume and HCC recurrence. Milan criteria significantly reduced tumor recurrences after liver transplantation, improving long-term survival. In conclusion, the efficacy of tumor selection criteria must be analyzed with the use of preoperative data, to avoid bias of the postoperative evaluation. Tumor volume and alfa-fetoprotein level may improve the selection of patients.

Entities:  

Mesh:

Year:  2004        PMID: 15350014     DOI: 10.1002/lt.20239

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

1.  Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization.

Authors:  Do Young Kim; Moon Seok Choi; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Sung Wook Shin; Sung Wook Choo; Young Soo Do; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

2.  Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival.

Authors:  Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.

Authors:  Asmaa I Gomaa; Alzhraa Al-Khatib; Wael Abdel-Razek; Mohammed Saad Hashim; Imam Waked
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

4.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

5.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25

Review 6.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

7.  Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

Authors:  Myron Schwartz; Igor Dvorchik; Sasan Roayaie; M Isabel Fiel; Sidney Finkelstein; J Wallis Marsh; John A Martignetti; Josep M Llovet
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

Review 8.  Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation.

Authors:  Mengqi Liu; Wenzhi Guo; Shuijun Zhang
Journal:  Int J Surg Oncol (N Y)       Date:  2017-11-16

9.  Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience.

Authors:  Sirina Ekpanyapong; Neil Philips; Bao-Li Loza; Peter Abt; Emma E Furth; Rashmi Tondon; Vandana Khungar; Kim Olthoff; Abraham Shaked; Maarouf A Hoteit; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2019-11-22

10.  The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  Matteo Ravaioli; Alessandro Cucchetti; Antonio Daniele Pinna; Vanessa De Pace; Flavia Neri; Maria Aurelia Barbera; Lorenzo Maroni; Giorgio Frega; Andrea Palloni; Stefania De Lorenzo; Maria Cristina Ripoli; Maria Abbondanza Pantaleo; Matteo Cescon; Massimo Del Gaudio; Giovanni Brandi
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.